2019

‘Terrace House Tokyo 2019-2020’ best moments so far

After 40 episodes, “Terrace House Tokyo 2019-2020” has gone on hiatus to protect the cast and crew amid the COVID-19 pandemic. It’s still unclear when, ...




2019

U.S. Military Operations Leave 132 Civilians Dead in 2019

[Dalsan Radio] US military operations in four countries in 2019 left 132 civilians dead, according to a report released Wednesday by the Pentagon.




2019

A 1990s Macedonian film set in 2019 foreshadows a xenophobic future

Like other sci-fi before it, it imagined the present year as a post-apocalyptic wasteland.




2019

A Rainy Day in New York (2019)




2019

A Rainy Day in New York (2019)

Genres: Comedy and Romance Running Time: 92 min. Directed by: Woody Allen Starring: Timothee Chalamet, Elle Fanning Synopsis: A young couple arrives in New York for a weekend where they are met with bad weather and a series of adventures.




2019

Greater Mekong Subregion East–West Economic Corridor Towns Development Project: Environmental Monitoring Report (July-December 2019)

Environmental monitoring reports describe the environmental issues or mitigation measures of a project. This document dated May 2020 is provided for the ADB project 43319-022 in the Lao People's Democratic Republic.




2019

Regional Cooperation and Integration Fund, 2007–2019

ONGOING EVALUATION. : This evaluation will assess the performance of the Regional Cooperation and Integration Fund (RCIF) against its establishment objectives and provide recommendations for its future directions.




2019

Climate Change Fund, 2008–2019

ONGOING EVALUATION. This evaluation will assess whether the Climate Change Fund (CCF) has been successful in facilitating greater investments in member countries to address climate change and provide recommendations for future directions of the fund. 




2019

Azərbaycan və Asiya İnkişaf Bankı (1999-2019): 20 illik tərəfdaşlıq

Bu nəşrdə Azərbaycanda şaxələndirilmiş, inklyuziv və dayanıqlı artım naminə Asiya İnkişaf Bankı (AİB) və Azərbaycan Hökuməti arasında əməkdaşlığın və birgə səylərin xülasəsi təqdim edilir.




2019

Water Financing Partnership Facility Annual Report 2019

This report covers the period January to December 2019 and presents the performance for the year against the annual work program and the cumulative performance to date.




2019

ASEAN Catalytic Green Finance Facility: Operations Plan 2019–2021

This document outlines the operations strategy and plan for the ASEAN Catalytic Green Finance Facility pilot phase (2019–2021).




2019

Urban Financing Partnership Facility Annual Report: January to December 2019

By end of 2019, the Urban Financing Partnership Facility (UFPF) assistance has led to a total of 152 completed projects, comprised of investment grants, technical assistance, direct charge activities, and project preparation studies.




2019

Dentons Hong Kong Wins at the <em>IFLR Asia-Pacific Awards</em> 2020 and Recognised at the <em>Asian-mena Counsel: Deals of the Year</em> 2019

Dentons Hong Kong has been recognised for its work at the IFLR Asia-Pacific Awards 2020 and Asian-mena Counsel: Deals of the Year 2019. These recognitions have highlighted the capabilities of the Firm in a wide range of practice areas.



  • Banking and Finance
  • Derivatives and Structured Products
  • Mergers and Acquisitions
  • Hong Kong

2019

Microchip Honored with Best of Show Award at Flash Memory Summit 2019

Microchip Honored with Best of Show Award at Flash Memory Summit 2019




2019

MicroSolutions January/February 2019

MicroSolutions January/February 2019




2019

HARMAN Showcases Today’s Ultimate In-Vehicle Experiences at CES 2019

CES 2019 - LAS VEGAS, NV – January 7, 2019 – HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co. Ltd., focused on connected technologies for automotive, consumer and enterprise markets, is showcasing at CES 2019 the vehicle’s role...




2019

HARMAN Rocks NAMM 2019

The NAMM Show is the world’s crossroads for music, sound and event technology products, attracting countless famous musicians and audiophiles to get a behind-the-scenes look at the latest cutting-edge solutions impacting the audio industry. From...




2019

#MakeMusicDay2019: Q&A with DJ Aasheesh Paliwal

For more than 70 years, some of world’s most respected musicians, producers and DJs have used HARMAN’s exceptional audio solutions and products from the studio to the stage. In honor of Make Music Day 2019, we sat down with Aasheesh Paliwal of HARMAN...




2019

Rockin’ Around the World with HARMAN: Make Music Day 2019

Nothing compares to the feeling you experience when you make music – whether you’re picking up an instrument for the first time or laying down your 100th track. As longstanding partners with the Make Music Alliance, HARMAN takes great pride in helping...




2019

Music Comes To Life at HARMAN Live Arena 2019

HARMAN Professional Solutions delighted scores of music fans in India with yet another successful edition of HARMAN Live Arena at The Palm Expo- country’s foremost exhibition of Professional Audio Products. A roster of incredible musicians rocked the...




2019

HARMAN Experts Discuss the Future of Automotive Audio at the 2019 AES International Conference

The car is expected to change more in the next five years than it has in the last fifty. What will the future of automotive audio look like? What challenges will suppliers and OEMs alike face in the coming years? At the upcoming International Conference...




2019

National Cybersecurity Awareness Month 2019: Q&A with HARMAN’s Asaf Atzmon

With the 2019 National Cybersecurity Awareness Month (NCSAM) upon us, we decided to get the latest download on the state of cybersecurity in the automotive industry from HARMAN’s Vice President & General Manager of Automotive Cybersecurity, Asaf Atzmon....




2019

General election 2019: Why you should think climate change not Brexit

Brexit may seem important right now, but whoever wins the election will be in charge halfway to 2030 – a crucial time in efforts to limit dangerous warming, says Jacob Aron




2019

HARMAN Shines at CES 2019 with Seven Innovation Awards

CES 2019 was a resounding success for HARMAN, resulting in seven Innovation Awards for some of HARMAN’s latest adaptive and connected audio products. The award winners include:   JBL Endurance DIVE, wireless sports headphones with MP3 player Under...




2019

It’s a Wrap! HARMAN’s Takeaways from CES 2019

From AI-powered virtual assistants, smart TVs, toothbrushes, and refrigerators to advancements in 5G connectivity, ride-sharing services and self-driving cars, the products and solutions announced in Las Vegas at the Consumer Electronics Show (CES) this...




2019

HARMAN Sets a News Record at the 2019 iF World Design Awards

One of the world’s largest and most prestigious design competitions, the iF World Design Awards have been recognizing excellence in design for the past 65 years. HARMAN has often been among the companies selected by the competition’s panel of design...




2019

HARMAN Teams Up with Leading OEMs to Bring Exceptional In-Car Audio Experiences to IAA 2019

HARMAN is gearing up to present its best-in-class audio technologies and solutions for many of the world’s foremost automotive OEMs at IAA 2019 from September 12-22 in Frankfurt/Main. Now in its 68th edition, IAA is the world’s largest motor show as well...




2019

HARMAN Ushers in the Future of Mobility at Auto Shanghai 2019

For eight consecutive days beginning on April 18th, the world’s largest motor show attracted hundreds of thousands of visitors from the automotive world. With China becoming a leading market for electromobility, autonomous driving and connected car...




2019

Spam and phishing in 2019

In the search for new ways to bypass spam filters, attackers are developing new methods of delivering their messages. This year, they made active use of various Google services, as well as popular social networks and video hosting sites.




2019

Financial Cyberthreats in 2019

Methodology Financial cyberthreats are malicious programs that target users of services such as online banking, e-money, and cryptocurrency, or that attempt to gain access to financial organizations and their infrastructure. These threats are usually accompanied by spam and phishing activities,… Read Full Article





2019

Subject Index to Volume 83 (2019)




2019

Author Index to Volume 83 (2019)




2019

Shellhaas RA, Burns JW, Barks JDE, Fauziya Hassan F, Chervin RD. Maternal Voice and Infant Sleep in the Neonatal Intensive Care Unit. Pediatrics. 2019;144(3):e30190288




2019

Ames SG, Davis BS, Marin JR, L. Fink EL, Olson LM, Gausche-Hill M, Kahn JM. Emergency Department Pediatric Readiness and Mortality in Critically Ill Children. Pediatrics. 2019;144(3):e20190568




2019

Ahmed A, Fend PI, Gaensbauer JT, Reves RR, Khurana R, Salcedo K, Punnoose R, Katz DJ, for the TUBERCULOSIS EPIDEMIOLOGIC STUDIES CONSORTIUM. Interferon-{gamma} Release Assays in Children <15 Years of Age. Pediatrics. 2020:145(1):e20191930




2019

Correction for Dietz et al., "2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission"




2019

Peer Reviewers for the Journal of the American Board of Family Medicine in 2019




2019

2019 Year in Review: Aerosol Therapy

Relevant publications related to medicinal and toxic aerosols are discussed in this review. Treatment of COPD includes a combination of long-acting bronchodilators and long-acting muscarinic antagonists. A combination of aclidinium bromide and formoterol fumarate was approved in the United States. The combination was superior to its components alone, as well as tiotropium and a salmeterol-fluticasone combination. Increased risk of an asthma exacerbation was reported in children exposed to electronic nicotine delivery systems. A smart inhaler capable of recording inspiratory flow was approved in the United States. The use of as-needed budesonide-formoterol was reported to be superior to scheduled budesonide and as-needed terbutaline for the treatment of adults with mild-to-moderate asthma. A survey among teens with asthma and their caregivers revealed a disagreement in the number of inhaled controller medications the teen was taking. Treatment with inhaled hypertonic saline resulted in a decreased lung clearance index in infants and preschool children with cystic fibrosis. Surgical masks were well tolerated and significantly decreased the burden of aerosolized bacteria generated by coughing in adults with cystic fibrosis. Inhaled liposomal amikacin in addition to guideline-based therapy was reported to be superior to guideline-based therapy alone in achieving negative sputum cultures in adult subjects with Mycobacterium avium complex pulmonary disease. During 2019, lung injury associated to e-cigarette or vaping was reported, including 60 casualties.




2019

2019 Year in Review: Neonatal Respiratory Support

Respiratory support of the critically ill neonate has steadily shifted from invasive to noninvasive forms of support. There have recently been a number of important advances in our understanding of the changes to neonatal resuscitation practices as they pertain to clinically important outcomes, mechanisms of gas exchange for high-flow nasal cannula, and best use of noninvasive ventilation and predicting response. Although the proportion of infants requiring intubation and mechanical ventilation has decreased, the most severely ill often still require intubation and ventilation. Recently, volume-targeted ventilation, high-frequency ventilation, and different methods of assessing weaning and extubation have been investigated. This review summarizes a number of important advances that have been made in the management of prematurity and neonatal respiratory distress syndrome.




2019

Erratum. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation in Type 1 Diabetes: A Prospective Parallel-Arm Cohort Study. Diabetes Care 2019;42:2042-2049




2019

Erratum. WASH Regulates Glucose Homeostasis by Facilitating Glut2 Receptor Recycling in Pancreatic {beta}-Cells. Diabetes 2019;68:377-386




2019

Women&#x2019;s experiences of diagnosis and management of polycystic ovary syndrome: a mixed-methods study in general practice

BackgroundPolycystic ovary syndrome (PCOS) is a common lifelong metabolic condition with serious associated comorbidities. Evidence points to a delay in diagnosis and inconsistency in the information provided to women with PCOS.AimTo capture women’s experiences of how PCOS is diagnosed and managed in UK general practice.Design and settingThis was a mixed-methods study with an online questionnaire survey and semi-structured telephone interviews with a subset of responders.MethodAn online survey to elicit women’s experiences of general practice PCOS care was promoted by charities and BBC Radio Leicester. The survey was accessible online between January 2018 and November 2018. A subset of responders undertook a semi-structured telephone interview to provide more in-depth data.ResultsA total of 323 women completed the survey (average age 35.4 years) and semi-structured interviews were conducted with 11 women. There were five key themes identified through the survey responses. Participants described a variable lag time from presentation to PCOS diagnosis, with a median of 6–12 months. Many had experienced mental health problems associated with their PCOS symptoms, but had not discussed these with the GP. Many were unable to recall any discussion about associated comorbidities with the GP. Some differences were identified between the experiences of women from white British backgrounds and those from other ethnic backgrounds.ConclusionFrom the experiences of the women in this study, it appears that PCOS in general practice is not viewed as a long-term condition with an increased risk of comorbidities including mental health problems. Further research should explore GPs’ awareness of comorbidities and the differences in PCOS care experienced by women from different ethnic backgrounds.




2019

A portrait of the artist: Homer and Milton&#x2019;s affliction




2019

Applicant gender and matching to first-choice discipline: a cross-sectional analysis of data from the Canadian Resident Matching Service (2013-2019)

Background:

Previous studies examining potential sex and gender bias in the Canadian Resident Matching Service (CaRMS) match have had conflicting results. We examined the results of the CaRMS match over the period 2013–2019 to determine the potential association between applicants’ gender and the outcome of matching to their first-choice discipline.

Methods:

In this cross-sectional analysis, we determined the risk of matching to one’s first-choice discipline in CaRMS by applicant gender and year, for all Canadian medical students who participated in the first iteration of the R-1 match for the years 2013 to 2019. We analyzed data in 3 categories of disciplines according to CaRMS classifications: family medicine, nonsurgical disciplines and surgical disciplines. We excluded disciplines with fewer than 10 applicants.

Results:

Match results were available for 20 033 participants, of whom 11 078 (55.3%) were female. Overall, female applicants were significantly more likely to match to their first-choice discipline (relative risk [RR] 1.03, 95% confidence interval [CI] 1.02–1.04). After adjustment for match year and stratification by discipline categories, we found that female applicants were more likely to match to family medicine as their first choice (RR 1.04, 95% CI 1.03–1.05) and less likely to match to a first-choice surgical discipline (RR 0.95, 95% CI 0.91–1.00) than their male peers. There was no significant difference between the genders in matching to one’s first-choice nonsurgical discipline (RR 1.01, 95% CI 0.99–1.03).

Interpretation:

These results suggest an association between an applicant’s gender and the probability of matching to one’s first-choice discipline. The possibility of gender bias in the application process for residency programs should be further evaluated and monitored.




2019

JACC: Basic to Translational Science 2019 Young Author Award Winner




2019

JACC: Basic to Translational Science 2019 Young Author Award Winner




2019

"ERS International Congress 2019: highlights from Best Abstract awardees". Lorna E. Latimer, Marieke Duiverman, Mahmoud I. Abdel-Aziz, Gulser Caliskan, Sara M. Mensink-Bout, Alberto Mendoza-Valderrey, Aurelien Justet, Junichi Omura, Karthi Srika




2019

Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus [Minireviews]

Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease 2019], or 2019-nCoV [2019 novel coronavirus]) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of infections by high-morbidity human coronaviruses, such as SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus, SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV–IFN-β) was shown to be effective in patients infected with SARS-CoV. LPV/RTV–IFN-β also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV–IFN-β against MERS-CoV in a transgenic humanized mouse model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, have suggested that proinflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aims to provide a summary of therapeutic compounds that have shown potential in fighting SARS-CoV-2 infections.




2019

Erratum. Therapeutic Inertia Is a Problem for All of Us. Clinical Diabetes 2019;37:105-106 (DOI: 10.2337/cd19-0009)